AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Glytec Goes Global, With Six New International Patent Allowances

May 23, 2019

WALTHAM, Mass.--(BUSINESS WIRE)--May 23, 2019--

The rise in diabetes is truly a global phenomenon. The World Health Organization has been vocal about the estimated 422 million people living with diabetes, saying: “the prevalence of diabetes is steadily increasing everywhere” and “diabetes and its complications impact harshly on the finances of individuals and their families, and the economies of nations.”Glytec recognizes that optimizing diabetes medications and making insulin a more effective and accessible option stands to benefit not only those living in the U.S., but people around the world. To that end, the company is growing its intellectually property portfolio on an international scale.

Robby Booth, SVP of Research & Development at Glytec, further explains why the company is pursuing worldwide protections: “Insulin remains significantly underutilized among people with type 2 diabetes, specifically those who’ve been unable to achieve their treatment goals. Our solutions help overcome many of the difficulties and challenges that cause therapeutic inertia among providers, including fears surrounding hypoglycemia. These latest patent allowances validate Glytec’s commitment to delivering industry-leading medication optimization solutions both domestically and abroad, and to helping mitigate the devastating personal and societal costs of diabetes.”

Glytec has recently received six new patent allowances from foreign regulatory agencies in Japan, Australia and Israel. The allowances address a variety of systems and methods for insulin titration and glycemic management. Select claims from among these patent allowances include [highly abridged and consolidated]:

“We are very pleased that the uniquenesses and sophistication of our eGlycemic Management System ® are being recognized by regulatory agencies outside the U.S.,” says Bob Leonard, President and CEO at Glytec. “The issues surrounding therapeutic inertia and insulin mismanagement are universal, and these patent allowances position Glytec to offer cutting-edge solutions across the globe.”

About Glytec

Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System ® is the only FDA-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190523005149/en/

CONTACT: Glytec

Joy Efron, 864-263-4160

Vice President Marketing

jefron@glytecsystems.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: SURGERY TECHNOLOGY DATA MANAGEMENT HARDWARE SOFTWARE PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY CARDIOLOGY CLINICAL TRIALS HOSPITALS MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH OTHER SCIENCE DIABETES FDA MEDICAL SUPPLIES NURSING SCIENCE GENERAL HEALTH MANAGED CARE

SOURCE: Glytec

Copyright Business Wire 2019.

PUB: 05/23/2019 08:00 AM/DISC: 05/23/2019 08:01 AM

http://www.businesswire.com/news/home/20190523005149/en

All contents © copyright 2019 The Associated Press. All rights reserved.